Considerations for Potential Global Expansion of Serum Institute of India

Authors

  • Veena Somasundaram Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, MD
  • Peter Soukas Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, Rockville, MD
  • Jenish Patel Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, Rockville, MD
  • Steven Ferguson Office of Technology Transfer, National Institutes of Health, Rockville, MD.

DOI:

https://doi.org/10.5912/jcb1006

Abstract

In a time of global vaccine shortages, especially for COVID-19 products, Serum Institute of India (SII) is straining to meet demand for vaccines in India. While this organization is not known worldwide, they entered into a recent alliance with AstraZeneca, who is partnered with Oxford University for Covid-19 vaccine, to manufacture their supply of vaccines for distribution in India. Several other such partnerships are also underway. And, SII is considering plans to become a much larger player, not only in India, but globally. This commentary is focused on if, when, where, why, and how global expansion could proceed. Our work was carried out as a class project to identify options and strategies appropriate for expansion and has been expanded subsequently as events continued to develop.

Downloads

Published

2021-12-23

Issue

Vol. 26 No. 4 (2021): Vol. 26 No. 4 (2021)

Section

Article